A cancer drug-turned-Alzheimer’s prospect now appears to have potential against a third disease, reportedly protecting animal models from Parkinson’s damage.
The receptor tyrosine kinase ErbB4 could be the latest gene for amyotrophic lateral sclerosis.
Silencing aberrant C9ORF72 mRNA helps normalize pathology in neurons, suggesting the transcripts are toxic to the cells.
Among cognitively healthy older adults, the rate of change in cerebrospinal fluid biomarkers helps predict who will develop Alzheimer’s disease.
Deep brain stimulation restores walking and swimming abilities in rats with spinal injuries, so long as a few nerve fibers remain intact.
A meta-analysis of four large genome-wide association studies turned up 11 new risk genes for Alzheimer’s disease.
More evidence that an antisense RNA strategy might work for certain types of ALS and FTD.
Screens of yeast and human-derived neurons uncover reasons for α-synuclein toxicity and potential ways to prevent it.
Researchers can vote for the winner of this year’s Geoffrey Beene NeuroDiscovery Challenge.
A repeat expansion that causes neurodegenerative disease is transcribed both forward and backward, producing sense and antisense RNAs and multiple polypeptides.
Some neurons stand out in the crowd. Researchers report that genomic variation among neurons in the brain is more common than originally thought.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
Stacked together, amyloid subunits absorb more light than they do as monomers. Are there implications for fibril detection?
Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
No filters selected